Novo Buys Another PRV; Thoughts on Potential Uses
Novo has reportedly purchased a PRV from Marinus for $110M (view SEC filing). There have been no press releases issued from Novo or Marinus. Of note, Novo previously purchased PRVs from Chemo Research SL and another from Medicines Development for Global Health (view article). However, the company has only used one of its PRVs in late 2020 to expedite FDA’s review of its Wegovy. Now, in addition to the newly acquired PRV from Marinus, Novo is believed to have two PRVs in its pocket. Below, FENIX has conducted an analysis and rationale for where the PRV may be used.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.